Comparative Pharmacology
Head-to-head clinical analysis: U GENCIN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: U GENCIN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
U-GENCIN vs ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Combination antibiotic and corticosteroid: Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane permeability, and inhibit cell wall synthesis, respectively; hydrocortisone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
Apply 3-4 times daily to affected area as a thin layer. Topical route. Frequency: every 6-12 hours.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Neomycin: 2-3h (systemic, IM); Bacitracin: 1.5h (systemic, IM); Polymyxin B: 6h (systemic, IV); Hydrocortisone: 1.5-2h (systemic). Topical: not applicable due to minimal absorption.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Renal: Neomycin (<1% absorbed, remainder fecal), Bacitracin (10-40% renal if absorbed, negligible), Polymyxin B (60% renal over 24h if absorbed), Hydrocortisone (metabolized, <1% unchanged renal; fecal for unabsorbed). Topical: negligible systemic absorption; fecal for unabsorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic